Drugs / NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells
NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02070406 | Jul 2014 → Dec 2018 | cancer of unknown primary site | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells | “NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV” NCT02070406 ↗ |
| Route | Intravenous | “autologous T cells IV” NCT02070406 ↗ |